Blueprint Medicines

Home » Blueprint Medicines

Secondary

Blueprint Medicines

Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined disease

Symbol

BPMC

Last Closing Price
$81.98

Shares
3,100,000

Effective Date
December 13, 2017

Underwriters
Goldman Sachs, Morgan Stanley, Cowen

To view the prospectus for Blueprint Medicines, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253